Daniel Kotz1, Jamie Brown, Robert West. 1. Cancer Research UK Health Behaviour Research Centre, University College London, London, WC1E 6BT, UK, d.kotz@maastrichtuniversity.nl.
Abstract
RATIONALE: Limited evidence from randomised controlled trials suggests that varenicline might be more effective than nicotine replacement therapy (NRT) in achieving abstinence from smoking. The comparative effectiveness of varenicline when prescribed under routine circumstances and in the general population has not been tested. OBJECTIVES: To compare the abstinence rates of smokers trying to stop having used varenicline vs. NRT on prescription (Rx) when provided with minimal professional support in the general population while adjusting for key potential confounders. METHODS: A large survey of a representative sample of the English population. Participants were 1,579 adults who smoked within the previous 12 months and made at least one quit attempt with varenicline or NRT Rx in their most recent quit attempt. The main outcome measure was self-reported abstinence up to the time of the survey, adjusted for key potential confounders including urges to smoke. A sensitivity analysis was conducted in subsamples in which the quit attempt started up to 6 months or more than 6 months ago. RESULTS: The adjusted odds of abstinence in users of varenicline were 1.76 (95 % CI = 1.22-2.53) times higher compared with users of NRT Rx. However, there was no detectable difference in the subsample of smokers who started their quit attempt more than 6 months ago (adjusted OR = 1.03, 95 %CI = 0.54-1.96). CONCLUSIONS: Varenicline use with minimal professional support in the general population of smokers appears more effective than NRT Rx in achieving short-term abstinence. However, this effect may disappear in the long-term. Research is needed to confirm this and establish what may underlie it.
RATIONALE: Limited evidence from randomised controlled trials suggests that varenicline might be more effective than nicotine replacement therapy (NRT) in achieving abstinence from smoking. The comparative effectiveness of varenicline when prescribed under routine circumstances and in the general population has not been tested. OBJECTIVES: To compare the abstinence rates of smokers trying to stop having used varenicline vs. NRT on prescription (Rx) when provided with minimal professional support in the general population while adjusting for key potential confounders. METHODS: A large survey of a representative sample of the English population. Participants were 1,579 adults who smoked within the previous 12 months and made at least one quit attempt with varenicline or NRT Rx in their most recent quit attempt. The main outcome measure was self-reported abstinence up to the time of the survey, adjusted for key potential confounders including urges to smoke. A sensitivity analysis was conducted in subsamples in which the quit attempt started up to 6 months or more than 6 months ago. RESULTS: The adjusted odds of abstinence in users of varenicline were 1.76 (95 % CI = 1.22-2.53) times higher compared with users of NRT Rx. However, there was no detectable difference in the subsample of smokers who started their quit attempt more than 6 months ago (adjusted OR = 1.03, 95 %CI = 0.54-1.96). CONCLUSIONS:Varenicline use with minimal professional support in the general population of smokers appears more effective than NRT Rx in achieving short-term abstinence. However, this effect may disappear in the long-term. Research is needed to confirm this and establish what may underlie it.
Authors: Ranjit K Dhelaria; Jennifer Friderici; Kelly Wu; Ella Gupta; Cyrus Khan; Michael B Rothberg Journal: Eur J Intern Med Date: 2012-05-03 Impact factor: 4.487
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: Laura L Biazzo; Desireé B Froshaug; Todd S Harwell; Heather N Beck; Cynthia Haugland; Stacy L Campbell; Steven D Helgerson Journal: Nicotine Tob Res Date: 2010-04-08 Impact factor: 4.244
Authors: John A Stapleton; Lucy Watson; Lucy I Spirling; Robert Smith; Andrea Milbrandt; Marina Ratcliffe; Gay Sutherland Journal: Addiction Date: 2007-11-19 Impact factor: 6.526
Authors: H-J Aubin; A Bobak; J R Britton; C Oncken; C B Billing; J Gong; K E Williams; K R Reeves Journal: Thorax Date: 2008-02-08 Impact factor: 9.139
Authors: Kevin M Gray; Erin A McClure; Nathaniel L Baker; Karen J Hartwell; Matthew J Carpenter; Michael E Saladin Journal: Addiction Date: 2015-03-29 Impact factor: 6.526
Authors: Daniel Kotz; Wolfgang Viechtbauer; Colin Simpson; Onno C P van Schayck; Robert West; Aziz Sheikh Journal: Lancet Respir Med Date: 2015-09-06 Impact factor: 30.700